Evidence map›Paper›PMID 33604999›Full record

ArticleMolecular oncology2021

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

Rory M Bade, Jennifer L Schehr, Hamid Emamekhoo, Benjamin K Gibbs, Tamara S Rodems, Matthew C Mannino, Joshua A Desotelle, Erika Heninger, Charlotte N Stahlfeld, Jamie M Sperger and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Rory M BadeCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Jennifer L SchehrCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.ORCID 0000-0003-2123-997X
Hamid EmamekhooDepartment of Medicine, University of Wisconsin-Madison, WI, USA.
Benjamin K GibbsCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Tamara S RodemsCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Matthew C ManninoCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Joshua A DesotelleDepartment of Medicine, University of Wisconsin-Madison, WI, USA.
Erika HeningerCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Charlotte N StahlfeldCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Jamie M SpergerCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Anupama SinghCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Serena K WolfeCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
David J NilesDepartment of Biomedical Engineering, University of Wisconsin-Madison, WI, USA.
Waddah ArafatCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
John A SteinharterLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
E Jason AbelCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
David J BeebeDepartment of Biomedical Engineering, University of Wisconsin-Madison, WI, USA.
Xiao X WeiLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Rana R McKayLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Toni K ChoueriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell AnalysisR01CA181648 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BERRY, SCOTT M, LANG, JOSHUA MICHAEL · 2014 to 2018
$1.6M
Microchannel cell-based assays to enable cancer researchR33CA137673 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J · 2009 to 2011
$1.4M
Special BD LSR FortessaS10OD018202 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI PATANKAR, MANISH S · 2014 to 2014
$351k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA181648NCI NIH HHS R33 CA137673NIH HHS S10 OD018202
6 · The paper itself

Abstract

Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous nature of clear cell RCC (ccRCC), tumor biopsies provide limited clinical utility, but liquid biopsies could overcome these limitations. Prior liquid biopsy approaches have lacked clinically relevant detection rates for patients with ccRCC. This study employed ccRCC-specific markers, CAIX and CAXII, to identify circulating tumor cells (CTC) from patients with metastatic ccRCC. Distinct subtypes of ccRCC CTCs were evaluated for PD-L1 and HLA-I expression and correlated with patient response to therapy. CTC enumeration and expression of PD-L1 and HLA-I correlated with disease progression and treatment response, respectively. Longitudinal evaluation of a subset of patients demonstrated potential for CTC enumeration to serve as a pharmacodynamic biomarker. Further evaluation of phenotypic heterogeneity among CTCs is needed to better understand the clinical utility of this new biomarker.

Indexed as

Neoplastic Cells, CirculatingAdultAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorFemaleHistocompatibility Antigens Class IHumansKidney NeoplasmsLiquid BiopsyMaleMiddle AgedNeoplasm MetastasisB7-H1 AntigenBiomarkers, TumorCD274 protein, humanHistocompatibility Antigens Class Ibiomarkerscirculating tumor cellsclear cell renal cell carcinomaexclusion-based sample preparationpharmacodynamicprognostic

Identifiers

PMID33604999
PMCPMC8410529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.